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Abstract
The continued burden of HIV in resource-limited regions such as parts of sub-Saharan Af-
rica, combined with adverse effects and potential risks of resistance to existing antiretroviral
therapies, emphasize the need to identify new HIV inhibitors. Here we performed a virtual
screen of molecules from the pan-African Natural Product Library, the largest collection of
medicinal plant-derived pure compounds on the African continent. We identified eight mole-
cules with structural similarity to reported interactors of Vpu, an HIV-1 accessory protein
with reported ion channel activity. Using in vitro HIV-1 replication assays with a CD4+ T cell
line and peripheral blood mononuclear cells, we confirmed antiviral activity and minimal cy-
totoxicity for two compounds, ixoratannin A-2 and boldine. Notably, ixoratannin A-2 retained
inhibitory activity against recombinant HIV-1 strains encoding patient-derived mutations
that confer resistance to protease, non-nucleoside reverse transcriptase, or integrase inhibi-
tors. Moreover, ixoratannin A-2 was less effective at inhibiting replication of HIV-1 lacking
Vpu, supporting this protein as a possible direct or indirect target. In contrast, boldine was
less effective against a protease inhibitor-resistant HIV-1 strain. Both ixoratannin A-2 and
boldine also inhibited in vitro replication of hepatitis C virus (HCV). However, BIT-225, a pre-
viously-reported Vpu inhibitor, demonstrated antiviral activity but also cytotoxicity in HIV-1
and HCV replication assays. Our work identifies pure compounds derived from African
plants with potential novel activities against viruses that disproportionately afflict resource-
limited regions of the world.
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Introduction
While recent advances in antiretroviral therapies (ARVs) have converted HIV to a chronic,
manageable condition in many high-income settings, barriers remain for their successful use in
low and middle-income countries with high disease burden; for example in parts of sub-Saha-
ran Africa. Here, despite recent significant progress to improve ARV access globally [1], the
challenges are complex and can include the fragility and uncertainty of ARV supply systems,
limited health care infrastructure, and the ability to retain patients in care [2, 3]. Moreover, the
side-effects of ARVs can result in poor adherence and increased risk of viral resistance [3, 4].
Drug resistance has been documented to all licensed ARVs [5], and transmission of resistant
HIV remains a major concern in many sub-Saharan African nations [6]. Thus new HIV thera-
pies that target additional viral proteins and are derived from local sources may be particularly
advantageous in these regions.
Natural products are a promising but undervalued resource for identifying new antivirals
[2]. Compounds derived from these sources can encompass structural diversity that falls out-
side the scope of chemical spaces found in many synthetic chemical screening libraries [1, 7];
as such, they have the potential to act via mechanisms distinct from those of conventional ther-
apies. With this advantage in mind, the pan-African Natural Product Library (p-ANAPL) was
formed to provide a centralized resource of pure compounds obtained from local plants with
medicinal properties supported by indigenous knowledge [8]. To date, the p-ANAPL contains
over 500 pure compounds and represents the largest physical collection of natural products
from medicinal plants in Africa [9]. The p-ANAPL thus represents an opportunity to screen
for new inhibitors of pathogens that disproportionately affect countries on the
African continent.
Currently, no licensed ARVs target the accessory proteins of HIV-1. Vpu is an 81–82 amino
acid transmembrane protein that is found in HIV-1 and a subset of SIVs and enhances viral
replication through multiple functions [10, 11]. Specifically, Vpu augments virion release by
downregulating CD4 and the host restriction factor BST2/CD317/tetherin, which otherwise
captures mature virions at the cell surface. While HIV-1 with defective Vpu can replicate in
vitro in some cell lines, these viruses generally display reduced spread, defects in viral budding,
and accumulation at the surface of infected cells. Consistent with these phenotypes, a Vpu-defi-
cient chimeric SIV/HIV strain replicated poorly and did not cause depletion of CD4+ lympho-
cytes in macaques [12]. Thus, effective replication of HIV in vivo requires a functional Vpu
protein, which makes it a promising drug target. Vpu is also reported by some to have ion
channel activity [13–15], although this is controversial [16] and the role of this activity in HIV-
1 replication remains uncertain [11]. Nevertheless, a few compounds with an acylguanidine
moiety including hexamethylene amiloride and BIT-225 (Fig. 1A) are reported to inhibit both
Vpu ion channel activity in lipid bilayers and viral replication in vitro [11, 17]. However, the
cellular toxicity often associated with this class of compounds is an obstacle toward their fur-
ther development as antivirals [18, 19].
Here we performed a virtual screen of the p-ANAPL to identify molecules with structural
similarity to BIT-225 and other reported Vpu ion channel interactors, with the goal of identify-
ing novel inhibitors of HIV-1. Of eight compounds identified in this virtual screen, both ixora-
tannin A-2 and boldine displayed antiviral activity in cell-based HIV-1 and hepatitis C virus
(HCV) replication assays. We further investigated the mechanisms of action of these antiviral
compounds using recombinant HIV-1 strains that either lacked Vpu or encoded patient-de-
rived sequences resistant to established ARVs.
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Fig 1. Putative HIV-1 Vpu inhibitors identified from virtual screening of the p-ANAPL. A, Structures of four molecules predicted to interact with the Vpu
ion channel [20]. B, Alignment of four molecules. Chemical substituents that define a shared pharmacophore are highlighted. C, Eight p-ANAPLmolecules
containing aspects of the shared pharmacophore. For each compound, root mean square deviation (RMSD) values are shown in parentheses.
doi:10.1371/journal.pone.0121099.g001
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Materials and Methods
Chemicals, cells, and reagents
Boldine, ECG, EA, and rimantadine hydrochloride were purchased from Sigma. Geshoidin,
2MA, KA, PA, and ixoratannin A-2 were obtained as previously described [21–25]. CEM-GXR
and Huh-7.5 cells were cultured and infected as described previously [26, 27].
BIT-225 was synthesized as previously reported [28]. 1H and 13C NMR spectra were re-
corded on a Bruker Ascend spectrometer at 400 and 100 MHz, respectively. Proton NMR data
were reported as multiplicities: s for singlet, d for doublet, dd for double of doublets, t for trip-
let, q for quartet, br s for broad singlet, and m for multiplet. Chemical shifts were reported in
parts per million (ppm) and coupling constants in hertz (Hz). For 1H NMR spectra, CDCl3, or
DMSO-d6 was used as solvent and served as the internal standard at δ 7.26, or 2.54, respective-
ly. For 13C NMR spectra, multiplicities were established by DEPT experiments and CDCl3 or
DMSO-d6 was used as solvent, which served as the internal standard at δ 77.16 (CDCl3), or
39.52 (DMSO-d6). The purity of each analogue was confirmed by HPLC analysis and using a
Finnigan Surveyor HPLC system (Thermo Scientific) consisting of a solvent degasser, a quater-
nary pump and a Surveyor Auto-sampler Plus module. Chromatographic separation was
achieved using gradient elution system consisting of 10–60% acetonitrile in distilled water con-
taining either 5mm ammonium acetate or 0.1% acetic acid. Solvent was pumped through a
C18 analytical column (HALO C18 2.7 μM, 4.6 X 50 mm) and delivered at 1.2–2.0 ml/min
over 5 min. The column was maintained at room temperature using a column oven. All com-
pounds were dissolved in methanol and detected using a variable wavelength UV detector at
254 nm. The purity was calculated from an integral of peaks and described in terms of percent-
age (%). Low-resolution mass spectra were obtained using Waters ZQ instrument equipped
with ESCi ion source with in-like Waters 2695 HPLC system controlled by MassLynx 4.1 soft-
ware. 1H NMR (400 MHz, CDCl3): δ 1.91 (s, 2H), 3.90 (s, 3H), 7.76 (dd, J = 1.6 Hz, J = 8.5 Hz,
1H), 7.83 (d, J = 8.5 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 8.0 (s, 1H), 8.1 (s, 1H), 8.15 (dd, J =
1.6 Hz, J = 8.5 Hz, 1H), 8.2 (s, 1H), 8.59 (s, 1H). 13C NMR (100 MHz, DMSO-d6): 21.5, 122.2,
122.4, 124.9, 126.6, 127.1, 128.8, 128.9, 130.0, 131.2, 131.7, 135.2, 136.1, 136.8, 163.2, 172.5, 175.9.
MS (ESI) m/z: [M + H]+ Calculated for C16H15N5O: 294.13; Found: 294.4. Purity:>99%.
The following reagents were obtained through the NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: pNL4-3 from Dr. MalcomMartin (Catalog #114) and p210-13 (HIV-
1Δvpu) from Dr. Ronald Desrosiers: (Catalog #2484) [29].
Virtual screening
The chemical structures of four known Vpu blockers were retrieved from the literature [20].
The 3D conformations were generated using the (default) MMFF94x forcefield [30], using the
MOE software tool [31], following the protocol previously implemented by Daveu et al. [32].
The force field parameters were kept at their default values of the Strain Limit of 4 kcal/mol
and the Conformations limit of 250 conformations/molecule. The other settings were kept at
their default values, with the exception of the Split Output option being turned off, and the
Input Filters being turned off. A pharmacophore query is created using the Pharmacophore
Query Editor, implemented in MOE. A query consists of a set of constraints on the location
and type of pharmacophoric features, which can be used to search a database of molecular con-
formations. In this work, the query was created and saved, in order to be used later in a phar-
macophore search. While a query may be created without a reference molecule (e.g., the most
active molecule in our database), in this study, the common pharmacophore features of all four
compounds was used in the virtual screening of the p-ANAPL library (exported in .mdb format
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in MOE) [9]. The Pharmacophore Search was carried out on the p-ANAPL library [9], using
the pharmacophore module of the MOE package. Compounds with four out of the five com-
mon query features were selected as 'hits' in this search. The enrichment was measured against
a database that has already been enriched by a factor of 10 using MACCS fingerprints. The
Pharmacophore Consensus provided suggested features given an aligned set of molecules. In
this study, features that may contribute to the pharmacophore alignment of the four Vpu
blockers were located. How well the pharmacophore features of the hits fitted into the common
pharamcophore of Vpu actives was expressed as a root mean square deviation (RMSD), with
the compounds with lowest RMSD selected as hits.
Generation of viruses
HIV-1Δvpu was constructed by digesting plasmid p210-13 3’ Δ-vpu [29] with EcoRI and NheI
enzymes. The resulting DNA fragment was then ligated into wild-type pNL4-3 plasmid di-
gested with the same enzymes. HIV-1Δvpu and HIV-1NL4-3 viral stocks were prepared by trans-
fection of HEK-293T cells, as previously described [33]. Patient plasma-HIV-1 RNA sequences
were analyzed for resistance mutations using the HIV Drug Resistance Database Genotype Re-
sistance Interpretation Algorithm (hivdb.stanford.edu) [5]. Recombinant HIV-1NL4-3 express-
ing patient-derived HIV-1 sequences harboring resistance mutations to protease and reverse
transcriptase inhibitors (HIV-1PR+RT), reverse transcriptase inhibitors (HIV-1RT), and inte-
grase inhibitors (HIV-1INT) were generated by homologous recombination following co-trans-
fection as reported [34].
The intergenotypic chimeric HCV used in this study—Bi-Gluc-J4(1b)/JFH1(2a) containing
cell culture adaptive mutations in NS2 (T2996C) and NS3 (A4827T)—was previously de-
scribed [35] and subsequently modified to express Gaussia luciferase in the first cistron. HCV
stocks used for infection were generated by electroporation of in vitro transcribed RNA into
Huh-7.5.1 cells and pooling of supernatants harvested between 60–96 hr post-electroporation.
HCV infectivity was determined by limiting dilution assay as previously described [27].
HIV-1 replication assays in CEM-GXR cells
CEM-GXR cells are an immortalized CD4+ T-lymphocyte line engineered that naturally ex-
press the HIV-1 coreceptor CXCR4 and have been further engineered to express the HIV-1 co-
receptor CCR5 and a Tat-driven LTR-GFP expression cassette. As such, intracellular GFP ex-
pression indicates HIV-1 infection [26]. Cultures of 105 CEM-GXR cells were seeded into
96-well plates with RPMI-1640 media (Sigma) supplemented with penicillin/streptomycin plus
20% fetal calf serum (R20+), infected with HIV-1 at a multiplicity of infection of 0.03 (to
achieve 3% infected cells on Day 2), and incubated at 37°C and 5% CO2. 24 hours later, cells
were pelleted at 750 g and resuspended in R20+ containing compound or 0.1% DMSO. Stock
concentrations of all compounds were prepared in DMSO such that the final concentrations of
compounds in culture medium did not exceed 0.1% DMSO. Cells were then incubated at 37°C
and 5% CO2 for an additional 72 h. 5,000 cells from each culture were measured for cell toxicity
and GFP expression by flow cytometry. Flow cytometry data were analyzed using FlowJo v.
8.8.7 software (FlowJo LLC, Ashland, OR). Cell toxicity in HIV-1 infected cell cultures with
compound was calculated as the relative percentage of CEM-GXR cells that displayed charac-
teristic forward- and side-scatter parameters compared to control infected cultures plus 0.1%
DMSO. Background GFP expression in uninfected cultures was set at 0.05% GFP-positive
cells. For each experiment, all data points were obtained in triplicate. All data are reported as
the mean ± s.e.m. from at least 3 independent experiments performed with different virus
stocks and/or performed on different days. However, all experiments that compare HIV-1NL4-3
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and mutant HIV-1 were performed in parallel. EC50 and CC50 values for each compound were
calculated from at least four concentrations. Statistical analyses were performed using Student’s
unpaired t test, with a p value< 0.05 plus a Bonferroni correction to adjust for multiple com-
parisons considered significant.
HIV-1 replication assays in peripheral blood mononuclear cells (PBMCs)
PBMCs from HIV-1 negative subjects, purchased commercially (StemCell Technologies, Van-
couver, Canada), were maintained in RPMI-1640 media (Sigma) supplemented with penicillin/
streptomycin plus 10% fetal calf serum (R10+). 72 h prior to viral infection, PBMCs were stim-
ulated by addition of 5 μg/mL phytohaemaglutanin (PHA) (Day 0) and maintained in R10+
medium supplemented with 100 units/mL human IL-2. At Day 3 following cellular activation,
3x105 cells were infected with HIV-1NL4-3 at a multiplicity of infection of 0.003 (0.3% infected
cells) and incubated at 37°C for 6h, followed by wash and re-suspension in fresh R10+ medium
supplemented with 100 units/mL human IL-2 and with or without compounds at defined
concentrations. Culture supernatants were collected and replaced with fresh medium supple-
mented with human IL-2 every 3 days (i.e., Days 6, 9, and 12) with or without fresh com-
pounds. Viral replication at day 12 was monitored by measuring cell culture supernatant levels
of p24Gag by ELISA (XpressBio, Frederick, MD) following manufacturer’s instructions.
Cytotoxicity was determined by ViaCount Assay (Millipore). Briefly, Day 3 PHA-activated
PBMCs (3105) were cultured in R10+ supplemented with 100 units/mL human IL-2 in the
presence of 0.1% DMSO or compounds at defined concentrations. At Day 5, 15 μL of each
PBMC culture was mixed with Guava ViaCount Reagent at a 1:10 dilution. Data were collected
using a Guava EasyCyte HT Flow Cytometer (Millipore).
HCV cell culture, viral replication assays
HCV cell culture was performed as described previously [27]. Briefly, 4104 Huh-7.5 cells were
seeded into 24-well plates and incubated at 37°C and 5% CO2 overnight. Cells were then in-
fected with HCV (multiplicity of infection = 0.3) for 6 hours, followed by removal of HCV and
incubation with fresh medium containing compounds at stated concentrations. Cultures were
then incubated for 72 hours, with no more than 0.1% DMSO present in culture medium. Cells
were then trypsinized, resuspended in culture medium, and stained with the 9E10 alexa-fluor-
conjugated antibody to NS5A [27]. Cells were fixed and analyzed for NS5A fluorescence by
flow cytometry, and data were analyzed using FlowJo software. Cell toxicity in HCV infected
cell cultures with compound was calculated as the relative percentage of Huh-7.5 cells that dis-
played characteristic forward- and side-scatter parameters compared to control infected cul-
tures plus 0.1% DMSO. For each culture, NS5A fluorescence was determined as the percent
gated cells relative to percent gated cells in infected cultures plus 0.1% DMSO. All experiments
were performed in at least duplicate in at least two independent experiments.
Results
Virtual screening for potential Vpu inhibitors
Previously reported ligand docking simulations predict that BIT-225 and three additional acyl-
guanidine-containing molecules interact with the pore of a pentameric bundle formed by Vpu
transmembrane helices [20] (Fig. 1A). Superposition of these four structures indicates a com-
mon pharmacophore consisting of one or more aromatic rings separated by a short spacer
from an H-bond acceptor and one or more H-bond donors (Fig. 1B). On the basis of this phar-
macophore, we used a probability densities method [9] to virtually screen the entire p-ANAPL.
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We then selected molecular configurations that emphasize low strain energy, similar shape to
the four reference molecules, and similar overlap of aromatic, donor, and acceptor atoms.
From this screen, 8 molecules exhibited features similar to the original pharmacophore, defined
here as an RMSD> 0.6 (Fig. 1C).
Identification of HIV-1 inhibitors
To assess the effects of these eight compounds on cell viability and HIV-1 replication, we in-
fected a GFP-reporter CEM CD4+ T cell line (CEM-GXR) [26] with the NL4-3 strain of HIV-1
(HIV-1NL4-3). Briefly, cells were infected with HIV-1NL4-3 at a multiplicity of infection of 0.03
(Day 0), followed by removal of HIV-1 and addition of compound (or 0.1% DMSO vehicle
control) 24 hours later (Day 1) and incubation for an additional 72 hours to allow HIV-1
spread (Days 2–4). On Days 2 and/or 4, the percent HIV-1 infected (i.e., GFP-expressing) cells
was measured by flow cytometry. Cell viability was assessed by measuring the percentage of
cells displaying normal forward- and side-scatter parameters in drug-treated, HIV-1 infected
cultures compared to 0.1% DMSO-treated, HIV-1 infected control cultures. As shown in Fig. 2,
the percent infected (GFP-positive) cells in HIV-1NL4-3 infected cultures tripled between Day 2
to Day 4 (e.g., 3.14 to 10.80% in Fig. 2A). HIV-1NL4-3 replication was unaffected by the presence
of 0.1% DMSO vehicle control (Fig. 2B).
Consistent with the previously described cytotoxic effects of Vpu inhibitor BIT-225 in T cell
cultures [19, 36], treatment of infected CEM-GXR cells with this compound resulted in sub-
stantial cellular toxicity at all tested concentrations (CC50 = 10.7 μM; Table 1; Fig. 3A), which
obscured the detection of any antiviral activity in this assay. Two naturally-derived com-
pounds, 1,5,7-trimethoxyphenanthrene-2,6-diol (PA) and knipholone anthrone (KA), also dis-
played cytotoxicity at low concentrations (CC50< 30 μM) and so measures of their antiviral
activity were not reliably obtained. However, of the remaining six compounds identified from
the virtual screen, two exhibited reproducible inhibition of HIV-1 replication, defined here at
an EC50< ~50 μM (Fig. 3B), at concentrations that were not obviously cytotoxic. These com-
pounds were ixoratannin A-2 (CC50 = 57.5 μM; EC50 = 34.4 μM; selectivity index [SI] = 1.7)
and boldine (CC50 = 207.7 μM; EC50 = 50.2 μM; SI = 4.1; Table 1).
The effects of BIT-225, boldine, and ixoratannin A-2 were also assessed for cell viability and
HIV-1 replication in peripheral blood mononuclear cells (PMBCs). Similar to CEM-GXR cells,
we also observed substantial cytotoxicity in PBMCs in the presence of BIT-225 (CC50 =
12.8 μM; Fig. 3C); in contrast, viability remained above 85% relative to PBMCs in 0.1% DMSO
for all assessed concentrations of boldine or ixoratannin A-2. However, a clear reduction in
HIV-1 replication in PBMCs, as measured by viral p24Gag protein levels in PBMC culture su-
pernatants, was observed with 10 μM BIT-225 (i.e., 31.8% reduced replication; Fig. 3D). For
boldine, HIV-1 replication was substantially reduced only at high concentrations (47.0% re-
duced replication at 100 μM), suggesting a roughly 2-fold reduction in activity in PBMCs rela-
tive to CEM-GXR cells (Table 1). In contrast, HIV-1 replication in PBMCs in the presence of
ixoratannin A-2 roughly corresponded to its activity in CEM-GXR cells (39.0% reduced repli-
cation at 25 μM). Unfortunately, due to the limits of available ixoratannin A-2, we were unable
to assess its activity in PBMCs concentrations higher than 25 μM.
Anti-HIV mechanisms of action of ixoratannin A-2 and boldine
To investigate the mechanisms by which ixoratannin A-2 and boldine may block HIV-1 repli-
cation, we used a previously-reported HIV-1NL4-3 strain lacking the Vpu coding region (HIV-
1Δvpu) [29]. We also constructed recombinant HIV-1NL4-3 strains harboring protease, reverse
transcriptase, and/or integrase sequences of HIV-1 strains from patients who had developed
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resistance to the protease inhibitor Indinavir (IND), the non-nucleoside reverse transcriptase
inhibitor Efavirenz (EFV), and/or the integrase inhibitor Raltegravir (RAL) (denoted HIV-1PR+RT,
Fig 2. HIV-1 replication in CEM-GXR cells. A, Flow cytometry data showing GFP expression from uninfected (top), HIV-1NL4-3-infected cells (center), and
HIV-1NL4-3-infected cells plus 100 μM boldine (bottom) at Days 2 and 4. Values at the bottom-right of each panel indicate the percent GFP-positive (i.e., HIV-
infected) cells. Background GFP expression is set to 0.05% in uninfected cell cultures.B, Percent infected cells, as measured by GFP expression, in cultures
of CEM-GXR cells +/- HIV-1 and +/- 0.1% DMSO vehicle control. Data in B andA are from independent experiments.
doi:10.1371/journal.pone.0121099.g002
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HIV-1RT, and HIV-1INT, respectively). Re-sequencing of the recombinant viruses confirmed
the presence of multiple mutations known to confer resistance to IND, EFV, and/or RAL
(Table 2) [5].
As expected, replication of both HIV-1NL4-3 and HIV-1Δvpu in CEM-GXR cells were inhib-
ited in the presence of 0.1 μM EFV, IND, or RAL (Fig. 4). In contrast, HIV-1PR+RT, HIV-1RT,
and HIV-1INT were significantly less sensitive to these drugs in a pattern consistent with specif-
ic resistance mutations. For example, HIV-1PR+RT replication was 2.6-fold higher than HIV-
1NL4-3 in the presence 0.1 μM EFV and 2.7-fold higher in the presence of 0.1 μM IND. Similar-
ly, HIV-1RT replication in CEM-GXR cells was 3.4-fold greater than HIV-1NL4-3 replication in
the presence of 0.1 μM EFV. Finally, HIV-1INT replication was 1.7-fold higher than HIV-1NL4-3
in the presence of 0.1 μM RAL, confirming that these mutations underlie resistance to specific
ARVs. The residual replication of HIV-1NL4-3 and HIV-1Δvpu in the presence of licensed
ARVs to which they are susceptible is likely attributable to our high infection of cell cultures
for 24 hours prior to addition of compounds.
When compared to HIV-1NL4-3, 75 μM of ixoratannin A-2 was 1.4-fold less effective at in-
hibiting HIV-1Δvpu in CEM-GXR cells, a modest difference that was nevertheless statistically
significant (Fig. 5A). This difference translated into a 1.5-fold increase in the EC50 (EC50 =
52.0 μM against HIV-1Δvpu vs. 34.4 μM against HIV-1NL4-3; Table 3). This supports Vpu as a
direct or indirect target, among possibly others, of ixoratannin A-2. Furthermore, although not
reaching statistical significance, treatment with 75 μM of boldine was 1.3-fold less effective at
inhibiting HIV-1Δvpu (Fig. 5B), resulting in an EC50> 100 μM compared to 50.2 μM for HIV-
1NL4-3 (Table 3). This suggests that boldine may primarily confer anti-HIV-1 activity by acting
on additional targets other than Vpu.
While 75 μM of ixoratannin A-2 was somewhat less effective in blocking replication of
HIV-1PR+RT and HIV-1INT in CEM-GXR cells (both exhibited 1.5-fold higher replication than
HIV-1NL4-3 at this concentration; Fig. 5C), the EC50s of ixoratannin A-2 against these resistant
HIV-1 strains approximated that of HIV-1NL4-3 (Table 3). This suggests that ixoratannin A-2
exhibits comparable activity against wild-type HIV-1NL4-3 as well as HIV-1 strains resistant to
currently-licensed protease, reverse transcriptase, and integrase inhibitors, except perhaps at
very high concentrations. In contrast, treatment with boldine resulted in< 50% inhibition of
all ARV-resistant HIV-1 strains at concentrations up to 75 or 100 μM (Fig. 5D), corresponding
to EC50s> 100 μM for these ARV-resistant strains compared to 50.2 μM for HIV-1NL4-3
(Table 3). In particular, boldine was less effective at blocking replication of HIV-1PR+RT, with
1.4 and 1.5-fold greater replication vs. HIV-1NL4-3 at 25 and 75 μM, suggesting that it may act
Table 1. Cell toxicity and inhibition of HIV-1NL4-3 in CEM-GXR cells by p-ANAPL compounds.
Compound Cell toxicity (CC50, μM) HIV-1NL4-3 inhibition (EC50, μM)
BIT-225 10.7 n/d
geshoidin >10 >100
2MA 50.9 >100
KA 0.9 n/d
boldine >100 50.2
PA 26.8 n/d
ECG >100 >100
EA 52.3 >100
ixoratannin A-2 57.5 34.4
n/d, not determined.
doi:10.1371/journal.pone.0121099.t001
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Fig 3. Effects of p-ANAPL compounds on cell viability and in vitroHIV-1 replication. A, CEM-GXR cell viability at Day 4 in the presence of p-ANAPL
compounds at defined concentrations. Data are normalized to the percent of viable cells in an HIV-1NL4-3-infected culture plus 0.1% DMSO. B, HIV-1
replication in CEM-GXR cells at Day 4 in the presence of compounds. Data are normalized to percent HIV-1NL4-3-infected cells plus 0.1% DMSO. Dose-
response plots of ixoratannin A-2 and boldine are highlighted with blue and green arrows, respectively. C, PBMC viability at Day 5 in the presence of p-
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as an HIV-1 protease inhibitor with some cross-resistance to reverse transcriptase and
integrase inhibitors.
Anti-hepatitis C virus activity of ixoratannin A-2 and boldine
As ixoratannin A-2 and boldine potentially acted on multiple HIV-1 targets and exhibited no
obvious cellular toxicity, we asked whether these compounds blocked replication of other vi-
ruses. We therefore assessed the effects of ixoratannin A-2, boldine, and BIT-225 on replication
of HCV, which also encodes a viral ion channel and protease [37]. Using an established cell cul-
ture system [27], Huh-7.5 cells were infected with an intergenotypic chimera between the J4
(genotype 1b) and JFH1 (genotype 2a) strain of HCV for 6 hours, followed by incubation with
fresh medium containing compounds at defined concentrations. Infected cells were then incu-
bated for an additional 72 hours. NS5A expression, a marker of HCV infection, was then de-
tected by flow cytometry.
Interestingly, at 72 hours post-infection, no major cytotoxicity (defined here as at least 20%
fewer gated cells compared to infected cells + 0.1% DMSO vehicle control) was observed at any
concentration with the exception of BIT-225 (Fig. 6A) with a calculated CC50 of 52.9 μM. How-
ever, BIT-225 did inhibit HCV replication in surviving Huh-7.5 cells, with 37.5% inhibition at
30 μM (Fig. 6B). Boldine also inhibited HCV replication with efficacy similar to rimantadine
[38], a previously-reported inhibitor of the HCV-encoded p7 ion channel and HCV replication
(e.g., 36.0% and 40.7% inhibition at 50 μM for boldine and rimantadine, respectively). In con-
trast, ixoratannin A-2 was the most potent compound at all tested concentrations (Fig. 6B),
with>50% inhibition of HCV at 30 μM and a calculated EC50 of 23.0 μM. The relatively low
activity of control inhibitors like rimantadine and BIT-225 compared to previous reports [38,
39] are likely to reflect the stringent antiviral conditions of this assay, which features a 6 hour
infection step before addition of drug in addition to a high multiplicity of infection (0.3).
Discussion
The development of new therapeutics against HIV is necessary to counter the risks of resis-
tance to established ARVs, particularly in countries with high disease burden and limited
health care infrastructure. Here we used a common pharmacophore derived from a series of re-
ported HIV-1 Vpu ion channel interactors [20] to perform a virtual screen of p-ANAPL mole-
cules to identify compounds with potential new modes of action against HIV. Of eight
molecules identified in this screen, two were observed to inhibit in vitroHIV-1 replication in a
CD4+ T cell line as well as PBMCs. These compounds, ixoratannin A-2 and boldine, also had
ANAPL compounds. Data are normalized to the percent of viable cells in an uninfected culture plus 0.1% DMSO.D, HIV-1 replication in PBMCs at Day 12 in
the presence of p-ANAPL compounds, as measured by p24Gag levels in cell culture supernatants. Data are normalized to percent HIV-1NL4-3-infected cells
plus 0.1% DMSO.
doi:10.1371/journal.pone.0121099.g003
Table 2. Properties of HIV-1 strains lacking Vpu or encodingmutations that underlie resistance to ARVs.
HIV-1 strain Protein Primary mutation(s) Resistance to ARVs tested
Δvpu vpu vpu open reading frame deleted n/a
PR+RT protease M46L, I54V, I84V, L90M IND + EFV
reverse transcriptase K101E, Y181C, G190A
RT reverse transcriptase K103N, V108I, M230L EFV
INT integrase N155H RAL
doi:10.1371/journal.pone.0121099.t002
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limited effects on cell viability when compared to their antiviral activities (e.g., selectivity indi-
ces (SIs) for ixoratannin A-2 and boldine in CEM-GXR cells were 1.7 and 4.1, respectively). Of
the remaining six compounds, four did not inhibit HIV-1 replication in CEM-GXR cells at up
to 100 μM, while two were highly cytotoxic (CC50s< 30 μM), which precluded detection of an-
tiviral activity in this assay. We note that the limited anti-HIV activity of boldine and ixoratan-
nin A-2, when compared to licensed ARVs, emphasizes that these compounds are at best
starting points for new therapeutic development and are unlikely to exhibit any clinical benefit
themselves. The limited anti-HIV activities of boldine and ixoratannin A-2 are also supported
by experiments with HIV-1-infected PBMCs, where the antiviral activities of these compounds
at 10 μM did not improve on the antiviral activity of 10 μM BIT-225, a molecule currently in
phase I clinical trials [40].
Nevertheless, our results validate the strategy of using common pharmacophores from
known and putative ion channel inhibitors to identify new antiviral compounds from natural
products. Our results also highlight the p-ANAPL, a library of pure compounds derived from
African plants with locally-reported medicinal properties [8, 9], as a viable source of therapeu-
tically-relevant antiviral prototypes. As our initial screen here focused only on potential inhibi-
tors of Vpu ion channel activity with structural similarity to known and putative Vpu
inhibitors, additional compounds from p-ANAPL may also inhibit HIV-1 replication via simi-
lar or additional mechanisms. Assessment of these and other compounds for inhibitory activity
against HIV and other pathogens is therefore underway.
Notably, we found that the Vpu inhibitor BIT-225, despite showing activity against HIV-1
and HCV replication in line with previous reports [19, 39], was highly toxic to CEM-GXR T
cells (CC50 = 10.7 μM) and PBMCs (CC50 = 12.8 μM). The high cytotoxicity of BIT-225 in
CEM-GXR cells precluded our ability to measure its antiviral activity in these cells, although
antiviral activity of 10 μM BIT-225 was observed in PBMCs (31.8% inhibition). Our results
Fig 4. Replication of HIV-1NL4-3, HIV-1Δvpu, and drug-resistant HIV-1 strains in CEM-GXR cells.Data shown are at Day 4 in the presence of 0.1 μM of
established ARVs, relative to the replication rate of each HIV-1 strain in the presence of 0.1% DMSO vehicle control. *, p< 0.004 vs. HIV-1NL4-3 replication.
doi:10.1371/journal.pone.0121099.g004
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contrast with previous studies that show minimal cytopathic effects of BIT-225 in monocyte
derived macrophages (CC50s = 167–284 μM) and SupT1 and CEM-SS cells (CC50s = 32–
Fig 5. Effects of ixoratannin A-2 and boldine on replication of HIV-1Δvpu and ARV-resistant HIV-1 strains in CEM-GXR cells. In all experiments, data
are normalized to the replication rate of each HIV-1 strain plus 0.1% DMSO at Day 4.A-B, effects of ixoratannin A-2 (A) and boldine (B) on HIV-1NL4-3 and
HIV-1Δvpu replication.C-D, effects of ixoratannin A-2 (C) and boldine (D) on replication of ARV-resistant HIV-1 strains.*, p< 0.008 vs. HIV-1NL4-3 at the same
concentration of ixoratannin A-2 or boldine. ǂ, p< 0.008 for strain HIV-1PR+RT and HIV-1INT vs. HIV-1NL4-3 at same concentration of ixoratannin A-2.
doi:10.1371/journal.pone.0121099.g005
Table 3. Calculated EC50s of ixoratannin A-2 and boldine on HIV-1Δvpu and ARV-resistant HIV-1 strains.
Compound EC50 (μM)
HIV-1NL4-3 HIV-1Δvpu HIV-1PR+RT HIV-1RT HIV-1INT
ixoratannin A-2 34.4 52.0 36.4 33.7 38.4
boldine 50.2 >100 >100 >100 >100
doi:10.1371/journal.pone.0121099.t003
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67 μM) [36, 39]. However, bovine viral diarrhea virus-infected Madin-Darby bovine kidney
cells were also reported to be sensitive to low levels of BIT-225 (CC50 = 11.6 μM) [41], and we
also observed that Huh-7.5 cells (CC50 = 52.9 μM) are relatively tolerant to BIT-225 when com-
pared to CEM-GXR cells and PBMCs. Thus, certain cell-types and cell lines, in addition to sub-
sets of cells in PBMC cultures, likely differ in their sensitivity to BIT-225. Despite this,
however, BIT-225 has advanced to early clinical trials to treat HCV and HIV-1 [41], where ini-
tial reports suggest that the disease-modifying activity of BIT-225 may be sufficient to over-
come the potential adverse effects of cellular toxicity.
Of the two virtual screening hits found here, ixoratannin A-2 exhibited the lower selectivity
index of blockade of HIV-1 replication over cytotoxicity in CEM-GXR cells (SI = 1.7). Ixora-
tannin A-2 is a doubly-linked, A-type proanthrocyanidin trimer isolated from the Ixora cocci-
nea shrub of western Nigeria and traditionally used to treat infections, hypertension, menstrual
irregularities, chronic ulcers, and skin diseases [21]. This compound contains three epicatechin
units and has structural similarity to other flavanols and flavan-3-ols previously reported to
have anti-HIV activity by targeting reverse transcriptase and integrase [2, 40, 42–43]. While we
did not observe significant differences in the inhibition of EFV and RAL-resistant HIV-1
strains by ixoratannin A-2, except in some cases at 75 μM, these discrepancies could reflect dif-
ferential modes of inhibition by ixoratannin A-2 compared to the mutant reverse transcriptase
and integrase sequences examined here.
Evidence for Vpu as a possible target of ixoratannin A-2 comes from its modest (1.4-fold)
inability to inhibit HIV-1 lacking a functional Vpu protein (HIV-1Δvpu). However, additional
Fig 6. Effects of compounds on HCV replication. A, Cell viability at 72 h post-infection in the presence of compounds at defined concentrations. Data are
normalized to the percent of viable cells in a HCV-infected culture plus 0.1% DMSO. B, HCV replication at 72 h post-infection in the presence of compounds.
Data are normalized to percent HCV-infected cells plus 0.1% DMSO.
doi:10.1371/journal.pone.0121099.g006
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proof that ixoratannin A-2 directly blocks Vpu ion channel activity awaits detailed electrophys-
iology-based pharmacology studies in whole cells, which have been reported by some groups
[14, 15, 44] but are disputed by others [16]. Moreover, as HIV-1Δvpu resistance to ixoratannin
A-2 was incomplete and occurred only at high concentrations (i.e., 75 μM), additional viral or
host targets may exist. These possibilities require further study. Notably, ixoratannin A-2 in-
hibited multiple ARV-resistant HIV-1 strains with comparable EC50s to wild-type HIV-1NL4-3,
indicating that it retains activity against HIV-1 harboring mutations that confer resistance to
IND, EFV, or RAL, except at high concentrations. Thus ixoratannin A-2 and related com-
pounds may indicate a potential therapeutic path toward overcoming resistance to EFV, IND,
and RAL.
Boldine is an alkaloid aporphine that was originally isolated from the Chilean boldo tree
(Peumus boldus) but is also found in many plants of African origin [45]. It is best characterized
for its antioxidant, anti-inflammatory, and hepatoprotective properties and has been proposed
as a potential therapy to treat cardiovascular, neurodegenerative, metabolic, and other inflam-
mation-based diseases [46]. It is also reported to have antiplasmodial, anticancer, immuno-
modulatory and anticonvulsant properties [45]. Antiviral activity is also reported for other
apomorphines, for example against HIV, poliovirus, rhinovirus, herpes simplex virus type 1,
and influenza, although boldine itself was assessed in only a few of these studies, where no anti-
polio virus or anti-herpes virus activity was observed [47–51].
While HIV-1Δvpu was less responsive to treatment with boldine at multiple concentrations,
these differences were not statistically significant and suggest that the discovery of boldine by
virtual screening for similarity to other HIV-1 Vpu inhibitors may have been fortuitous. How-
ever, boldine has been reported to block hERG potassium channel currents, as measured by
two electrode voltage clamp studies in Xenopus oocytes (IC50 = 19.3 μM) [52]. It is also an in-
hibitor of human 5-HT3 receptor ion channels, nicotinic acetylcholine receptors, and calcium
channels at low micromolar concentrations [45, 53–55]. Thus, given its precedent as a promis-
cuous ion channel inhibitor, the anti-Vpu activity of boldine should also be confirmed in
electrophysiological studies. We also found increased viral replication of all ARV-resistant viral
strains, and HIV-1PR+RT in particular, in the presence of boldine (e.g., 1.4-fold increased repli-
cation vs. HIV-1NL4-3). Thus, in addition to Vpu, HIV-1 protease, reverse transcriptase, and
integrase are all potentially targets of boldine.
We also observed that ixoratannin A-2 and boldine inhibit HCV replication with similar or
improved efficacy to rimantadine, an HCV ion channel inhibitor that is undergoing patient re-
cruitment for a phase II clinical trial [56]. The activity of ixoratannin A-2 is also improved rela-
tive to BIT-225, which is also undergoing clinical trials for HCV [41]. Although recently-
developed second-generation HCV protease inhibitors like Simeprevir display dramatically
higher cure rates in HIV/HCV co-infected patients when compared to established pegylated in-
terferon/ribavirin combination HCV therapies [57], morbidity in HIV/HCV co-infected pa-
tients—notably hepatocellular carcinoma and advanced liver damage—remains a concern
[58]. Furthermore, it remains unclear whether these second-generation inhibitors can be effec-
tively distributed to regions with limited healthcare infrastructure that has hampered access to
ARVs. Therefore, ixoratannin A-2 and boldine could represent possible scaffolds for therapies
to target HCV or HIV-1/HCV co-infection in the absence of established alternatives. These re-
sults also support the potential of ixoratannin A-2 and boldine for broad-spectrum antiviral ac-
tivity, which should be assessed in additional viral systems.
No additional compounds were identified here to inhibit HIV-1. PA resembles stilbenoids
isolated from the fruit of Combretaceae hereroense with reported antibacterial activity [22], and
KA also has reported antibacterial, antifungal, antiprotozoal, antitumor, and antioxidant prop-
erties [23]. However, both of these compounds were cytotoxic in our viral assay (respective
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CC50s = 26.8 and 0.9 μM), making them poor candidates for further antiviral development at
this stage. The potential antiviral activities of PA and KA will need to be assessed using alterna-
tive viral, enzymatic, or electrophysiological assays. We also did not observe antiviral activity
for epicatechin gallate (ECG), which was previously reported to have anti-reverse transcriptase
and integrase activities in enzymatic assays [2, 21, 40] but no antiviral activity in T cell lines
[59]. Similarly, ellagic acid (EA) derivatives are reported to block HIV protease, integrase, and
reverse transcriptase [60–62] but we did not observe these activities in our viral replication
system. Finally, geshoidin, previously reported to inhibit glutathione transferases [24], and1-
(3-acetyl-2,4-dihydroxy-6-((3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-yl)oxy)phenyl)-
4,5-dihydroxy-2-methylanthracene-9,10-dione (2MA), which is structurally similar to com-
pounds reported with tumor cytotoxic activity [25], also did not inhibit HIV-1 in our assay.
In conclusion, we report that pure compounds obtained from African medicinal plants, as
part of the p-ANAPL, are a viable source of prototype antivirals. We identify new chemical
scaffolds that may inform further development of natural product and/or synthetic HIV-1 in-
hibitors that act on ARV-resistant viral strains and alternative viral targets like Vpu, and we
also provide new options for future anti-HIV and/or HCV therapies that might be suitable for
local production.
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